SCHEMBL256814

SCHEMBL256814

COCc1ccc(C(=O)c2cccn2C)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
MAPT P10636 2/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAOB P27338 1/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197226 0.86 SMN1; SMN2 (0.43) SMN1; SMN2HSD17B10NPC1RAB9AMAPT
SCHEMBL257354 0.82 SMN1; SMN2 (0.44) SMN1; SMN2HSD17B10NPC1RAB9AMAPT
SCHEMBL15197130 0.82 SMN1; SMN2 (0.44) SMN1; SMN2HSD17B10NPC1RAB9AMAPT
SCHEMBL257367 0.81 MAPT (0.45) SMN1; SMN2HSD17B10NPC1RAB9AMAPT
SCHEMBL15197086 0.80 SMN1; SMN2 (0.50) SMN1; SMN2HSD17B10NPC1RAB9AMAPT
SCHEMBL15100732 0.77 TSHR (0.46) SMN1; SMN2HSD17B10NPC1RAB9AMAPT
SCHEMBL23635697 0.74 EPHX2 (0.49) HSD17B10RAB9AALDH1A1KDM4EL3MBTL1
SCHEMBL256851 0.73 ALDH1A1 (0.47) SMN1; SMN2NPC1RAB9AMAPTPKM
SCHEMBL20798434 0.72 CA1 (0.49) SMN1; SMN2HSD17B10RAB9AMAPTALDH1A1
SCHEMBL256840 0.72 HPGD (0.50) SMN1; SMN2NPC1RAB9AMAPTNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SMN1; SMN2 2704/4885HSD17B10 146/4885NPC1 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.